232 related articles for article (PubMed ID: 18071073)
1. Platelet sarcoplasmic endoplasmic reticulum Ca2+-ATPase and mu-calpain activity are altered in type 2 diabetes mellitus and restored by rosiglitazone.
Randriamboavonjy V; Pistrosch F; Bölck B; Schwinger RH; Dixit M; Badenhoop K; Cohen RA; Busse R; Fleming I
Circulation; 2008 Jan; 117(1):52-60. PubMed ID: 18071073
[TBL] [Abstract][Full Text] [Related]
2. Oxidant stress impairs in vivo reendothelialization capacity of endothelial progenitor cells from patients with type 2 diabetes mellitus: restoration by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone.
Sorrentino SA; Bahlmann FH; Besler C; Müller M; Schulz S; Kirchhoff N; Doerries C; Horváth T; Limbourg A; Limbourg F; Fliser D; Haller H; Drexler H; Landmesser U
Circulation; 2007 Jul; 116(2):163-73. PubMed ID: 17592079
[TBL] [Abstract][Full Text] [Related]
3. Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces circulating platelet activity in patients without diabetes mellitus who have coronary artery disease.
Sidhu JS; Cowan D; Tooze JA; Kaski JC
Am Heart J; 2004 Jun; 147(6):e25. PubMed ID: 15199366
[TBL] [Abstract][Full Text] [Related]
4. Peroxisome proliferator-activated receptor gamma agonist improves arterial stiffness in patients with type 2 diabetes mellitus and coronary artery disease.
Yu J; Jin N; Wang G; Zhang F; Mao J; Wang X
Metabolism; 2007 Oct; 56(10):1396-401. PubMed ID: 17884451
[TBL] [Abstract][Full Text] [Related]
5. Alterations in platelet Ca2+ signalling in diabetic patients is due to increased formation of superoxide anions and reduced nitric oxide production.
Schaeffer G; Wascher TC; Kostner GM; Graier WF
Diabetologia; 1999 Feb; 42(2):167-76. PubMed ID: 10064096
[TBL] [Abstract][Full Text] [Related]
6. Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces clinical inflammatory responses in type 2 diabetes with coronary artery disease after coronary angioplasty.
Wang G; Wei J; Guan Y; Jin N; Mao J; Wang X
Metabolism; 2005 May; 54(5):590-7. PubMed ID: 15877288
[TBL] [Abstract][Full Text] [Related]
7. The S1P(2) receptor expressed in human platelets is linked to the RhoA-Rho kinase pathway and is down regulated in type 2 diabetes.
Randriamboavonjy V; Badenhoop K; Schmidt H; Geisslinger G; Fisslthaler B; Fleming I
Basic Res Cardiol; 2009 May; 104(3):333-40. PubMed ID: 19139947
[TBL] [Abstract][Full Text] [Related]
8. Platelet signalling abnormalities in patients with type 2 diabetes mellitus: a review.
El Haouari M; Rosado JA
Blood Cells Mol Dis; 2008; 41(1):119-23. PubMed ID: 18387322
[TBL] [Abstract][Full Text] [Related]
9. Fenofibrate and rosiglitazone improve quality of lipoproteins in patients with type 2 diabetes mellitus.
Vrablík M; Dobiásová M; Stulc T; Kasalová Z; Dolezalová R; Prázný M; Fait T; Ceska R
Neuro Endocrinol Lett; 2008 Feb; 29(1):146-50. PubMed ID: 18283261
[TBL] [Abstract][Full Text] [Related]
10. Keratinocyte-derived vascular endothelial growth factor biosynthesis represents a pleiotropic side effect of peroxisome proliferator-activated receptor-gamma agonist troglitazone but not rosiglitazone and involves activation of p38 mitogen-activated protein kinase: implications for diabetes-impaired skin repair.
Schiefelbein D; Seitz O; Goren I; Dissmann JP; Schmidt H; Bachmann M; Sader R; Geisslinger G; Pfeilschifter J; Frank S
Mol Pharmacol; 2008 Oct; 74(4):952-63. PubMed ID: 18599600
[TBL] [Abstract][Full Text] [Related]
11. Increased expression of plasma membrane Ca(2+)ATPase 4b in platelets from hypertensives: a new sign of abnormal thrombopoiesis?
Dally S; Chaabane C; Corvazier E; Bredoux R; Bobe R; Ftouhi B; Slimane H; Raies A; Enouf J
Platelets; 2007 Nov; 18(7):543-9. PubMed ID: 17957572
[TBL] [Abstract][Full Text] [Related]
12. A study on the action of vitamin E supplementation on plasminogen activator inhibitor type 1 and platelet nitric oxide production in type 2 diabetic patients.
Vignini A; Nanetti L; Moroni C; Testa R; Sirolla C; Marra M; Manfrini S; Fumelli D; Marcheselli F; Mazzanti L; Rabini RA
Nutr Metab Cardiovasc Dis; 2008 Jan; 18(1):15-22. PubMed ID: 17949955
[TBL] [Abstract][Full Text] [Related]
13. Cinnamtannin B-1 from bay wood reduces abnormal intracellular Ca2+ homeostasis and platelet hyperaggregability in type 2 diabetes mellitus patients.
Bouaziz A; Salido S; Linares-Palomino PJ; Sanchez A; Altarejos J; Bartegi A; Salido GM; Rosado JA
Arch Biochem Biophys; 2007 Jan; 457(2):235-42. PubMed ID: 17118329
[TBL] [Abstract][Full Text] [Related]
14. Peroxisome proliferator-activated receptor-gamma-mediated effects in the vasculature.
Duan SZ; Usher MG; Mortensen RM
Circ Res; 2008 Feb; 102(3):283-94. PubMed ID: 18276926
[TBL] [Abstract][Full Text] [Related]
15. Effect of uncoupling endothelial nitric oxide synthase on calcium homeostasis in aged porcine endothelial cells.
Perrier E; Fournet-Bourguignon MP; Royere E; Molez S; Reure H; Lesage L; Gosgnach W; Frapart Y; Boucher JL; Villeneuve N; Vilaine JP
Cardiovasc Res; 2009 Apr; 82(1):133-42. PubMed ID: 19176602
[TBL] [Abstract][Full Text] [Related]
16. Evidence for iNOS-dependent peroxynitrite production in diabetic platelets.
Tannous M; Rabini RA; Vignini A; Moretti N; Fumelli P; Zielinski B; Mazzanti L; Mutus B
Diabetologia; 1999 May; 42(5):539-44. PubMed ID: 10333045
[TBL] [Abstract][Full Text] [Related]
17. Peroxisome proliferator-activated receptor gamma agonism modifies the effects of growth hormone on lipolysis and insulin sensitivity.
Krag MB; Nielsen S; Guo Z; Pedersen SB; Schmitz O; Christiansen JS; Jørgensen JO
Clin Endocrinol (Oxf); 2008 Sep; 69(3):452-61. PubMed ID: 18331610
[TBL] [Abstract][Full Text] [Related]
18. Platelet cNOS activity is reduced in patients with IDDM and NIDDM.
Martina V; Bruno GA; Trucco F; Zumpano E; Tagliabue M; Di Bisceglie C; Pescarmona G
Thromb Haemost; 1998 Mar; 79(3):520-2. PubMed ID: 9531033
[TBL] [Abstract][Full Text] [Related]
19. Review of the pleiotropic effects of peroxisome proliferator-activated receptor gamma agonists on platelet function.
Borchert M; Schöndorf T; Lübben G; Forst T; Pfützner A
Diabetes Technol Ther; 2007 Oct; 9(5):410-20. PubMed ID: 17931049
[TBL] [Abstract][Full Text] [Related]
20. Rosiglitazone produces a greater reduction in circulating platelet activity compared with gliclazide in patients with type 2 diabetes mellitus--an effect probably mediated by direct platelet PPARgamma activation.
Khanolkar MP; Morris RH; Thomas AW; Bolusani H; Roberts AW; Geen J; Jackson SK; Evans LM
Atherosclerosis; 2008 Apr; 197(2):718-24. PubMed ID: 17765245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
